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ABSTRACT
Background Radical prostatectomy and radiotherapy 
are standard treatments for localized prostate cancer. 
When making decisions about treatment, it is important 
to not only consider medical information such as the pa-
tient’s age, performance status, and complications, but 
also the impact on quality of life (QOL) after treatment.
Our purpose was to compare health related quality of 
life (HRQOL) after robot-assisted laparoscopic radi-
cal prostatectomy (RARP) versus radiation therapy 
in Japanese patients with localized prostate cancer 
retrospectively.
Methods Patients with localized prostate cancer 
receiving RARP or radiotherapy at Tottori University 
Hospital between October 2010 and December 2014 
were enrolled in a retrospective observational study 
with follow-up for 24 months to December 2016. The 
Medical Outcome Study 8-Item Short-Form Health 
Survey was performed before treatment and 1, 3, 6, 12, 
and 24 months post-treatment.
Results Complete responses to the questionnaire were 
obtained from 154/227 patients receiving RARP, 41/67 
patients receiving intensity-modulated radiation therapy, 
35/82 patients receiving low dose rate brachytherapy, 
and 18/28 patients given low dose rate brachytherapy 
plus external beam radiation therapy. The median 
physical component summary score of the Medical 
Outcome Study 8-Item Short-Form Health Survey was 
significantly lower at 1 month after prostatectomy than 
radiotherapy, but was similar for both treatments at 3 
months, and was significantly higher at 6, 12 and 24 
months after prostatectomy. The median mental compo-
nent summary score was also significantly lower in the 
prostatectomy group at 1 month, but not from 3 months 
onwards.
Conclusion Our study suggested that HRQOL was 
inferior at 1 month after RARP, however, recovered at 
3 months after RARP and was better than after radio-
therapy at 6, 12, and 24 months.
Key words health related quality of life; Medical Out-
come Study 8-Item Short Form Health Survey; prostate 
cancer; prostatectomy; radiation therapy
Radical prostatectomy and radiotherapy are standard 
treatments for localized prostate cancer. When making 
decisions about treatment, it is important to not only 
consider medical information such as the patient’s age, 
performance status, and complications, but also the im-
pact on quality of life (QOL) after treatment. It has been 
reported that patient’s satisfaction after robot-assisted 
laparoscopic radical prostatectomy (RARP) is associ-
ated with a high degree to a preoperative education.1 It 
is desirable for the patient, family members and health-
care professionals to engage in adequate consultation 
before a decision is made, but choosing among different 
treatment modalities is complicated.
In Japan, RARP was approved for national health 
insurance coverage in 2012, after which it rapidly be-
came popular,2 and has been established as a new stan-
dard therapy for localized prostate cancer. Regarding 
differences of therapeutic outcomes between RARP, 
laparoscopic radical prostatectomy (LRP), and retropu-
bic radical prostatectomy (RRP), the Japanese clinical 
Original ArticleYonago Acta Medica 2020;63(1):55–62 doi: 10.33160/yam.2020.02.008
Corresponding author: Yoko Miyoshi, RN, PhD
miyoc.45@tottori-u.ac.jp
Received 2019 November 22
Accepted 2020 January 17
Online published 2020 January 30
Abbreviations: BCR, biological recurrence; EBRT, external 
beam radiation therapy; HRQOL, health related quality of life; 
IMRT, intensity-modulated radiation therapy; LDR, low dose rate 
brachytherapy; LRP, laparoscopic radical prostatectomy; MCS, 
mental component summary; NCCN, National Comprehensive 
Cancer Network; PCS, physical component summary; PSA, 
prostate-specific antigen; QOL, quality of life; RARP, robot-
assisted laparoscopic radical prostatectomy; RPR, radical peri-
neal prostatectomy; RRP, retropubic radical prostatectomy; RP, 
role physical; SF-8, Medical Outcome Study 8-Item Short Form 
Health Survey; SF-36, Medical Outcome Study 36-Item Short 
Form Health Survey
brought to you by COREView metadata, citation and similar papers at core.ac.uk
provided by Tottori University Research Result Repository
56
Y. Miyoshi et al.
© 2020 Tottori University Medical Press
practice guideline indicates that RARP and LRP have 
the same oncological effect as RRP, while being less 
invasive, causing less blood loss, and achieving more 
rapid postoperative improvement of QOL (e.g., restora-
tion of urinary continence and sexual function).3
Previous studies have shown that health related 
quality of life (HRQOL) declines temporarily after 
laparoscopic or radical prostatectomy, but recovers 
within 1 year,4 and that postoperative QOL does not 
differ between RARP and open radical prostatectomy.5 
In Japanese patients, HRQOL may not show marked 
deterioration following RARP,6 and systematic reviews 
have found significantly better recovery of urinary con-
tinence7 and erectile function8 after RARP compared 
with both RRP and LRP.
Radiotherapy has adverse effects on the bladder, 
urethra, and rectum in the radiation field.9 Acute adverse 
events include urinary tract symptoms and defecation 
problems, while late events include urethral and rectal 
bleeding, ulceration, pain, urethral stenosis, and erectile 
dysfunction. Dysuria is the most common chronic tox-
icity of low dose rate brachytherapy (LDR),10, 11 while 
rectal bleeding is most frequently used as a functional 
endpoint in patients receiving external beam radiation 
therapy (EBRT).12 The risk of secondary cancer also 
cannot be ignored.13 Some studies have already com-
pared radical prostatectomy with radiotherapy, but there 
have been few comparisons of RARP with radiotherapy 
and most of the previous studies were not done in Japan. 
Thus, many points are unclear regarding the long-term 
HRQOL of Japanese patients after RARP.
Accordingly, we performed a comparat ive 
retrospective study of HRQOL after RARP versus 




This retrospective observational study enrolled patients 
with a diagnosis of localized prostate cancer who 
received RARP or radiotherapy at Tottori University 
Hospital between October 2010 and December 2014 
with follow-up for 24 months to the end of December 
2016. The number of patients receiving RARP, intensi-
ty-modulated radiation therapy (IMRT), LDR, and LDR 
combined with EBRT (LDR+EBRT) was 227, 67, 82, 
and 28, respectively.
Data collection
HRQOL was investigated before treatment and 1, 3, 6, 
12, and 24 months after treatment using the Japanese 
version of the SF-8 Health Survey (SF-8),14 which is a 
simplified version of the 36-Item Short-Form Health 
Survey (SF-36).15 The Japanese versions of both 
questionnaires have previously been validated. SF-8 
comprehensively measures health concepts in eight 
domains. The eight subscales are weighted to generate 
two summary scores, the physical component summary 
(PCS) and mental component summary (MCS). The 
cut-off value of the SF-8 is set at 50, with higher scores 
indicating better QOL. We obtained a license to use the 
SF-8 from iHope International (Kyoto, Japan).
Statistical analysis
Internal consistency of the SF-8 was assessed by calcu-
lating Cronbach’s α coefficient. When performing statis-
tical analysis, the Shapiro-Wilk test was initially carried 
out to assess the normality of data. Descriptive statistics 
were calculated for demographic characteristics. For 
comparison of characteristics between the patients 
receiving RARP or radiotherapy, age and prostate-
specific antigen (PSA) were compared by the Kruskal-
Wallis test, while the clinical stage, Gleason score, and 
nerve-sparing surgery were compared by Cramér’s 
coefficient of association. We explored the relation-
ship between pretreatment pathological stage as the 
independent variable and the treatment modality as the 
dependent variable by using multiple logistic regression 
analysis (partial method) in order to check the degree 
of influence of HRQOL. The median and interquartile 
range were calculated for HRQOL scores, and differ-
ences of the HRQOL score between RARP and radio-
therapy patients at each time point were tested by using 
the general linear model (repeated measures) followed 
by Scheffe’s multiple comparison test. Spearman’s rank 
correlation analysis was used to investigate correlations 
between SF-8 scores and the age or pretreatment PSA. 
A P value < 0.05 (two-sided) was considered significant. 
IBM SPSS Statistics for Windows (Version 25) was 
used for all analyses.
Informed consent
Informed consent was obtained from all individual par-
ticipants included in the study. Candidate participants 
were given a detailed explanation about the purpose 
and methods of the study, the expected benefits of par-
ticipation, a guarantee of anonymity, and the voluntary 
nature of participation. Written informed content was 
obtained from all participants before enrollment and 
anonymity of personal information was protected by 
de-identification.
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Ethical approval
All procedures performed in studies involving hu-
man participants were in accordance with the ethical 
standards of the Tottori University Faculty of Medicine 
Ethics Committee (approval no. 18A069) and with the 
1964 Helsinki declaration and its later amendments (as 
revised in Brazil 2013).
RESULTS
Patient characteristics
The percentage of patients providing complete respons-
es to the questionnaires was 67.8% (154/227) in the 
RARP group, while it was 61.2% (41/67) for patients re-
ceiving IMRT, 42.7% (35/82) for those treated by LDR, 
and 64.3% (18/28) for those treated with LDR+EBRT. 
The clinical characteristics of the study population are 
outlined in Table 1. In patients receiving RARP, IMRT, 
LDR, or LDR+EBRT, the mean age before treatment 
was 65.0, 71.6, 68.2, and 70.1 years, respectively. The 
mean pretreatment PSA level was 9.7, 27.1, 7.5, and 24.7 
mg/dL, respectively, and PSA was significantly lower 
in the RARP group than in patients receiving IMRT or 
LDR+EBRT. When Cramér’s V was calculated for the 
relation between clinical stage or the Gleason score and 
each treatment group, it was 0.37 for the clinical stage 
and 0.35 for the Gleason score, showing a weak relation 
with the disease stage.
As shown in Table 2, there was no correlation 
between pretreatment age or PSA and the mean SF-8 
score. Regarding National Comprehensive Cancer 
Network (NCCN) clinical risk, the risk classification 
ratios varied among the four groups. However, NCCN 
clinical risk had no strong influence on the treatment 
modalities (odds ratio: 0.61).
Table 1. Characteristics of the patients








 Mean ± SD 65.0 ± 6.4 71.6 ± 5.5** 68.2 ± 7.8 70.1 ± 6.7*
 Range 48–76 60–80 44–81 57–80
Pretreatment PSA (mg/dL)
 Mean ± SD 9.7 ± 6.6 27.1 ± 28.2** 7.5 ± 2.7 24.7 ± 20.9**
 Range 1.2–39.2 4.1–122.5 4.4–14.0 4.7–86.9
Clinical stage, n (%)
 T1c 32 (20.8) 1 (2.4) 8 (22.9) 2 (11.1)
 T2a 72 (46.8) 10 (24.4) 22 (62.9) 6 (33.3)
 T2b 6 (3.9) 5 (12.2) 0 4 (22.2)
 T2c 31 (20.1) 0 5 (14.3) 2 (11.1)
 T3a 12 (7.8) 18 (43.9) 0 4 (22.2)
 T3b 1 (0.6) 7 (17.1) 0 0
Gleason score, n (%)
 ≤ 6 33 (21.4) 2 (4.9) 14 (40.0) 0
 7 68 (44.2) 6 (14.6) 20 (57.1) 5 (27.8)
 ≥ 8 53 (34.4) 33 (80.5) 1 (2.9) 13 (72.2)
NCCN clinical risk, n (%)
 Low 18 (11.7) 1 (2.4) 7 (20.1) 0
 Intermediate 74 (48.1) 12 (29.3) 28 (80.3) 3 (16.7)
 High 62 (40.3) 28 (68.3) 0 15 (83.3)
Kruskal-Wallis test with Bonferroni's correction: ** P < 0.01, * P < 0.05 (two-sided)
Significant differences between the RARP group and other groups were assessed by the Kruskal-Wallis test for age and prostate-
specific antigen, or by Cramér's coefficient of association for clinical stage and Gleason score.
EBRT, external beam radiation therapy; IMRT, intensity-modulated radiation therapy; LDR, low dose rate brachytherapy; NCCN, 
National Comprehensive Cancer Network; PSA, prostate-specific antigen; RARP, robot-assisted laparoscopic radical prostatectomy; 
SD, standard deviation.
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HRQOL as determined by the SF-8
When internal consistency of the SF-8 was assessed 
for all subscales, Cronbach’s alpha was 0.9. Figure 1 
shows changes of the SF-8 scores (mean and standard 
deviation) for each treatment group during the follow-
up period, including the scores for each domain and the 
summary scores (PCS and MCS). The mean values for 
240 Japanese men aged 60–69 years (national standard 
value determined in 2007) are also displayed for 
comparison. Pretreatment scores showed no significant 
differences between the groups, except the scores for 
role physical (RP) and PCS. The results obtained during 
the follow-up period are described below, presented as 
the median value (interquartile range).
Physical functioning
The score for this domain was significantly lower in 
the RARP group than the LDR group at 1 month after 
treatment [41.5 (16.7–53.5] vs. 53.5 (27.6–53.5), P < 0.05]. 
There were no significant differences among the groups 
at 3 months after treatment. At 6, 12, and 24 months, the 
score was significantly higher in the RARP group than 
the IMRT group [53.5 (27.6–53.5) vs. 47.8 (27.6–53.5), 
53.5 (41.5–53.5) vs. 47.8 (27.6–53.5), and 53.5 (27.6–53.5) 
vs. 47.8 (27.6–53.5), respectively, all P < 0.05]. Also, 
the score was significantly higher in the RARP group 
than the LDR+EBRT group at 12 and 24 months after 
treatment [53.5 (41.5–53.5) vs. 44.6 (27.6–53.5) and 53.5 
(27.6–53.5) vs. 44.6 (16.7–53.5), respectively, both P < 
0.01].
Role physical
Before treatment, the score for this domain was sig-
nificantly higher in the RARP group than the IMRT 
group [54.1 (21.8–54.1) vs. 47.4 (27.9–54.1), P < 0.05]. 
Conversely, it was significantly lower in the RARP 
group than in the IMRT and LDR groups at 1 month 
after treatment [40.7 (21.8–54.1) vs. 47.4 (27.9–54.1) and 
40.7 (21.8–54.1) vs. 47.4 (21.8–54.1), respectively, both P 
< 0.05]. There were no significant differences among the 
groups at 3 and 6 months. However, the RARP group 
had a significantly higher score than the IMRT group at 
12 months [54.1 (27.9–54.1) vs. 47.4 (27.9–54.1), P < 0.01] 
and a significantly higher score than the LDR+EBRT 
group at 24 months [54.1 (27.9–54.1) vs. 44.0 (27.9–54.1), 
P < 0.05].
Bodily pain
The RARP group had a significantly lower score 
than the IMRT group at 1 month after treatment [52.5 
(21.7–60.4) vs. 52.5 (31.6–60.4), P < 0.05], but there 
were no between-group differences at 3 and 6 months 
after treatment. The RARP group showed a signifi-
cantly higher score than the IMRT group at 12 months 
[60.4 (38.2–60.4) vs. 52.5 (31.6–60.4), P < 0.05], while 
there were no significant between-group differences at 
24 months.
General health perception
There were no significant differences of the scores 
among the groups at 1, 3 and 6 months after treatment. 
The RARP group had a significantly higher score than 
the LDR+EBRT group at 12 months [50.3 (40.4–63.4) 
vs. 50.3 (34.4–58.5), P < 0.05), while there were no 
significant between-group differences at 24 months.
Vitality
There were no significant differences among the groups 
at 1 and 3 months after treatment. The RARP group 
had a significantly higher score than the IMRT group at 
6 months [53.7 (38.5–60.0) vs. 53.7 (28.7–60.0), P < 0.05], 
but there were no significant between-group differences 
at the other times.
Social functioning
The RARP group had a significantly lower score 
than the IMRT group at 1 month after treatment [37.7 
(26.0–55.1) vs. 55.1 (29.2–55.1), P < 0.01], but there were 
no significant between-group differences at the other 
times.
Role emotional
The RARP group had a significantly lower score 
than the IMRT group at 1 month after treatment [45.1 
Table 2. Correlations between age or preoperative PSA and the baseline SF-8 scores
N = 248 PF RP BP GH VT SF RE MH PCS MCS
Age –0.068 –0.045 0.029 0.049 0.023 0.039 0.010 0.046 –0.047 0.078
Pretreatment PSA 0.056 0.095 0.006 –0.004 0.018 0.033 0.137 0.087 0.021 0.104
Spearman's rank correlation coefficients are shown.
BP, bodily pain; GH, general health perception; MCS, mental component summary; MH, mental health; PCS, Physical component 
summary; PF, physical functioning, RE, role emotional; RP, role physical; SF, social functioning, VT vitality.
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Fig. 1. Mean SF-8 scores in each group. Error bars represent the standard deviation. RARP group: blue line; IMRT group: orange line; 
LDR group: yellow line; LDR+EBRT group: gray line; dashed green: national standard value. Although box-and-whisker plots are most 
frequently used for such data, a line graph has been employed here to facilitate comparison of multiple changes over time. Significant 
differences determined using the general linear model with Scheffe’s test: *P < 0.05, **P < 0.01 (two-sided).
1M, 1 month after treatment; 3M, 3 months after treatment; 6M, 6 months after treatment; 12M, 12 months after treatment; 24M, 24 
months after treatment; Normal, national standard value; Pre, pretreatment.
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(20.0–54.2) vs. 48.0 (31.4–54.2), P < 0.01], but there 
were no significant differences among the groups at 3, 
6, and 12 months. While the RARP group showed a 
significantly higher score than the LDR+EBRT group 
at 24 months [54.2 (31.4–54.2) vs. 48.0 (31.4–54.2), P < 
0.01].
Mental health
The score was significantly lower in the RARP group 
than the IMRT group at 1 month after treatment [50.7 
(27.6–56.9) vs. 50.7 (36.3–56.9), P < 0.05], but there 
were no significant differences among the groups at 
3 and 6 months. The RARP group had a significantly 
higher score than the IMRT group at 12 months [50.7 
(27.6–56.9) vs. 50.7 (36.3–56.9), P < 0.05) and a signifi-
cantly higher score than the LDR+EBRT group at 24 
months [56.9 (36.3–56.9) vs. 47.8 (36.3–56.9), P < 0.05].
Physical component summary
The pretreatment PCS score was significantly lower 
in the LDR+EBRT group than the RARP and LDR 
groups [47.6 (34.3–55.8) vs. 52.4 (21.6–63.7) and 47.6 
(34.3–55.8) vs. 52.6 (39.6–58.2), respectively, both P 
< 0.05], while the score was significantly lower in the 
RARP group than the LDR group at 1 month after 
treatment [43.4 (19.7–58.5) vs. 50.0 (25.7–56.7), P < 0.05]. 
There were no significant differences among the groups 
at 3 months. Scores were significantly higher in the 
RARP group than in the IMRT group at 6, 12, and 24 
months [52.1 (23.6–57.8) vs. 48.1 (25.4–56.6), P < 0.05; 
52.1 (37.1–59.1) vs. 48.5 (25.4–58.9), P < 0.01; and 52.7 
(28.4–58.5) vs. 47.9 (30.5–56.3), P < 0.05, respectively), 
as well as in the LDR+EBRT group at 12 and 24 months 
[52.1 (37.1–59.1) vs. 47.7 (34.0–56.6) and 52.7 (28.4–58.5) 
vs. 45.3 (28.3–56.6), respectively, both P < 0.05].
Mental component summary
While the RARP group had a significantly lower MCS 
score than the IMRT group at 1 month after treatment 
[46.5 (26.3–58.5) vs. 52.5 (29.7–57.2), P < 0.01], there 
were no significant differences among the groups at 
other times.
DISCUSSION
This retrospective study identified differences of 
HRQOL between patients receiving RARP and radio-
therapy who were followed for 24 months. The HRQOL 
was inferior at 1 month after RARP, and recovered at 
3 months after RARP and was better than after radio-
therapy at 6, 12, and 24 months. Treatment for prostate 
cancer is selected from among various options, such as 
surgery and radiotherapy, with QOL being an important 
consideration.16, 17 Several previous cross-sectional stud-
ies of HRQOL in prostate cancer patients have found 
no differences of HRQOL among treatment modali-
ties,18–20 but other studies have shown that QOL differs 
between radical prostatectomy (excluding RARP) and 
radiotherapy.21–23 Since no baseline data were provided 
in these reports, it is unclear whether the differences of 
HRQOL were actually related to treatment. In contrast, 
we obtained pretreatment data and we could properly 
assess the impact of treatment on HRQOL.
At 1 month after RARP, physical health was 
worse than at 1 month after radiotherapy, suggesting 
the influence of surgical invasion, such as pain or post-
prostatectomy urinary incontinence,2 on HRQOL, 
but the physical health of both groups was similar at 3 
months. By 6 months, HRQOL was better with RARP 
than radiotherapy, similar to the results of a previous 
study comparing HRQOL at 6 months between RRP 
and radiotherapy.24 At 12 months, physical health was 
worse in the LDR+EBRT group than the RARP group, 
and it tended to be below the national standard from 3 
months onward in patients receiving radiotherapy, sug-
gesting the influence of late adverse events.
At 1 month after RARP, mental health was also 
worse than at 1 month after radiotherapy, indicating that 
the postoperative state influenced HRQOL. No other 
between-group differences were detected, but scores 
for each group tended to be lower than the national 
standard.
The median life expectancy of prostate cancer 
patients undergoing radical prostatectomy was reported 
to be 13.8 years,25 so it is important to maintain long-
term QOL. Previous studies have found no significant 
difference of HRQOL at two years after surgery or 
external beam radiation.26, 27 A Japanese study showed 
that HRQOL was better after external radiotherapy than 
RRP,28 with higher scores for several SF-8 domains 
in patients receiving radiotherapy.23 However, the 
surgical patients did not undergo RARP and various 
radiotherapy modalities were included. Investigation 
of postoperative incontinence after RARP, RPR, RRP, 
and LRP has shown a superior recovery rate with 
RARP.2, 29 Taken together with the present results, we 
stress that HRQOL recovered at 3 months after RARP 
and was better than after radiotherapy at 6 months. The 
prevalence of urinary incontinence is influenced by 
surgical technique.7 RARP potentially reduces the risk 
of urinary incontinence, because significantly better 
recovery of continence after RARP has been reported.7 
It has already been reported that in terms of urinary 
incontinence, HRQOL remains worse at 24 months 
after RARP compared to other methods of prostate 
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cancer treatment30: Our results contrast with this, and 
the difference in results may be because Chien et al.’s 
study included patients who did not complete or had 
incomplete surveys. In our study, the radiation group 
included many high-risk patients, and none dropped out. 
However, it is difficult to simply compare the outcomes 
because the populations are different. To our knowledge, 
the present study was the first comparative retrospec-
tive study of post-treatment SF-8 scores among RARP, 
IMRT, LDR, and LDR EBRT without dropout cases. 
These findings could assist healthcare professionals to 
give patients information about the influence of treat-
ment on HRQOL.
Regarding the clinical characteristics of the study 
population, the IMRT and LDR+EBRT groups were 
older than the RARP group, while mean pretreat-
ment PSA was lower in the RARP group than the 
IMRT group and higher in the RARP group than the 
LDR+EBRT group. Although such differences could 
potentially influence HRQOL, there were no differences 
of pretreatment SF-8 scores, except for role physical 
and PCS. Also, age and PSA showed no relation with 
the SF-8 scores. Accordingly, we did not investigate the 
influence of age, PSA, clinical stage, and Gleason score 
at diagnosis on HRQOL, however no consensus has 
been reached.
This study had several limitations. First, the influ-
ence of neoadjuvant or adjuvant therapy on HRQOL 
was not considered.
Second, the LDR+EBRT group included many 
high-risk patients, and we cannot deny that this may 
have affected the quality of life after treatment in this 
group. Although there was no difference in the baseline 
of HRQOL score between groups, it was difficult to 
determine the influence of some bias where the RARP 
group had a better HRQOL score after treatment than 
the radiotherapy group.
In addition, in our study, the survival rate of pros-
tate cancer patients was 100% during the observation 
period, but regarding to the biological recurrence (BCR) 
was not evaluated. The BCR after radical treatment for 
prostate cancer is a major challenge for medical profes-
sionals. Also, disease-targeted QOL should be evaluated 
as well as HRQOL. Further studies are needed to sup-
port our findings, and required to examine the various 
effectiveness of these treatments with a greater number 
of patients and a longer follow-up period.
Despite such limitations, HRQOL after RARP 
was superior half a year up to 2 years compared with 
radiotherapy. It is possible that these results could help 
to select treatment for prostate cancer and provide 
information to support decision-making by patients 
and healthcare professionals. However, case risk bias 
and BCR should always be kept in mind, and this issue 
requires a separate study. From the perspective of pur-
suing further investigation, we have been continuing to 
accumulate cases and long-term follow-up data and plan 
to give a detailed report separately.
In conclusion, we demonstrated that the HRQOL 
after RARP was inferior at 1 month compared with 
radiotherapy, however, the HRQOL subsequently im-
proved, and was better than in radiotherapy patients’ 6, 
12, and 24 months. These findings could help to select 
treatment for localized prostate cancer and provide 
information to support decision-making by patients and 
healthcare professionals.
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